59
Participants
Start Date
February 29, 2016
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
Albiglutide Liquid Auto-injector
Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
Albiglutide Lyophilized DCC Pen Injector
Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
Placebo Liquid Auto-injector
Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
Placebo Lyophilized DCC Pen injector
Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
GSK Investigational Site, Austin
Lead Sponsor
GlaxoSmithKline
INDUSTRY